Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma

Molecular and Cellular Endocrinology

Volumn 325, Issue 1-2, 2010, Pages 110-117

  Trojanowicz, Bogusz ^a   Sekulla, Carsten ^a   Lorenz, Kerstin ^a   Köhrle, Josef ^b   Finke, Rainer ^a   Dralle, Henning ^a   Hoang Vu, Cuong ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Proteomic approach; Retinoic acid; Thyroid carcinoma

Indexed keywords

ENOLASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOCORTIN 2; PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE A; PEROXIREDOXIN 2; PROTEIN ENO1; PYRUVATE KINASE; PYRUVATE KINASE M1; PYRUVATE KINASE M2; RETINOIC ACID; TRANSKETOLASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; FEMALE; GOITER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IN VITRO STUDY; MALE; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEOMICS; THYROID ADENOMA; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION;

ADOLESCENT; ADULT; AGED; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; METABOLOME; MIDDLE AGED; PROTEOMICS; THYROID NEOPLASMS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77954387530     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2010.05.022     Document Type: Article

References (46)

1. Al-Ghoul M., Brück T.B., Lauer-Fields J.L., Asirvatham V.S., Zapata C., Kerr R.G., Fields G.B. Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J. Proteome Res. 2008, 7:4107-4118.
2. Baris O., Savagner F., Nasser V., Loriod B., Granjeaud S., Guyetant S., Franc B., Rodien P., Rohmer V., Bertucci F., Birnbaum D., Malthiery Y., Reynier P., Houlgatte R Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J. Clin. Endocrinol. Metab. 2004, 89:994-1005.
3. Bassi V., Vitale M., Feliciello A., De Riu S., Rossi G., Fenzi G. Retinoic acid induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 1995, 80:1129-1135.
4. Bernardini S., Melino G., Cortese C., Ballerini S., Annicchiarico-Petruzzelli M., Bernassola F., Corazzari M., Federici G. Modulation of glutathione transferase P1-1 activity by retinoic acid in neuroblastoma cells. J. Cell Biochem. 1999, 75:375-381.
5. Chikamori K., Hill J.E., Grabowski D.R., Zarkhin E., Grozav A.G., Vaziri S.A., Wang J., Gudkov A.V., Rybicki L.R., Bukowski R.M., Yen A., Tanimoto M., Ganapathi M.K., Ganapathi R. Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest. Leukemia 2006, 20:1809-1818.
6. Choi K.J., Piao Y.J., Lim M.J., Kim J.H., Ha J., Choe W., Kim S.S. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 2007, 67:3654-3662.
7. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R., Fleming M.D., Schreiber S.L., Cantley L.C. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-233.
8. Coelho S.M., de Almeida R.F., Corbo R., Breitenbach M.M., Carvalho D.P., Vaisman M. Isotretinoin as a diagnostic tool for localization of thyroid tissue in a thyroid cancer patient: a case report. Thyroid 2007, 17:893-896.
9. Cras A., Darsin-Bettinger D., Balitrand N., Cassinat B., Soulié A., Toubert M.E., Delva L., Chomienne C. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007, 26:4018-4024.
10. Delys L., Detours V., Franc B., Thomas G., Bogdanova T., Tronko M., Libert F., Dumont J.E., Maenhaut C. Gene expression and the biological phenotype of papillary thyroid carcinomas. Oncogene 2007, 26:7894-7903.
11. Du M.X., Sim J., Fang L., Yin Z., Koh S., Stratton J., Pons J., Wang J.J., Carte B. Identification of novel small-molecule inhibitors for human transketolase by high-throughput screening with fluorescent intensity (FLINT) assay. J. Biomol. Screen. 2004, 9:427-433.
12. Dragnev K.H., Petty W.J., Dmitrovsky E. Retinoid targets in cancer therapy and chemoprevention. Cancer Biol. Ther. 2003, 2:150-156.
13. Fernández C.A., Puig-Domingo M., Lomeña F., Estorch M., Camacho Martí V., Bittini A.L., Marazuela M., Santamaría J., Castro J., Martínez de Icaya P., Moraga I., Martín T., Megía A., Porta M., Mauricio D., Halperin I. Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J. Endocrinol. Invest. 2009, 32:228-233.
14. Fröhlich E., Fink I., Wahl R. Is transketolase like 1 a target for the treatment of differentiated thyroid carcinoma? A study on thyroid cancer cell lines. Invest. New Drugs 2009, 27:297-303.
15. Goretzki P.E., Simon D., Dotzenrath C., Schulte K.M., Röher H.D. Growth regulation of thyroid and thyroid tumors in humans. World J. Surg. 2000, 24:913-922.
16. Giusti L., Iacconi P., Ciregia F., Giannaccini G., Donatini G.L., Basolo F., Miccoli P., Pinchera A., Lucacchini A. Fine-needle aspiration of thyroid nodules: proteomic analysis to identify cancer biomarkers. J. Proteome Res. 2008, 7:4079-4088.
17. Granja F., Morari J., Morari E.C., Correa L.A., Assumpção L.V., Ward L.S. GST profiling may be useful in the screening for thyroid nodule malignancy. Cancer Lett. 2004, 209:129-137.
18. Handkiewicz-Junak D., Roskosz J., Hasse-Lazar K., Szpak-Ulczok S., Puch Z., Kukulska A., Olczyk T., Piela A., Paliczka-Cieslik E., Jarzab B. 13-cis-Retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res. 2009, 2:8.
19. Hansen L.A., Sigman C.C., Andreola F., Ross S.A., Kelloff G.J., De Luca L.M. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000, 21:1271-1279.
20. Haugen B.R., Larson L.L., Pugazhenthi U., Hays W.R., Klopper J.P., Kramer C.A., Sharma V. Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J. Clin. Endocrinol. Metab. 2004, 89:272-280.
21. Hoang-Vu C., Bull K., Schwarz I., Krause G., Schmutzler C., Aust G., Köhrle J., Dralle H. Regulation of CD97 protein in thyroid carcinoma. J. Clin. Endocrinol. Metab. 1999, 84:1104-1109.
22. Hoffmann S., Rockenstein A., Ramaswamy A., Celik I., Wunderlich A., Lingelbach S., Hofbauer L.C., Zielke A. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol. Cell Endocrinol. 2007, 264:74-81.
23. Jeong H., Kim Y.R., Kim K.N., Choe J.G., Chung J.K., Kim M.K. Effect of all-trans retinoic acid on sodium/iodide symporter expression, radioiodine uptake and gene expression profiles in a human anaplastic thyroid carcinoma cell line. Nucl. Med. Biol. 2006, 33:875-882.
24. Knauf J.A., Fagin J.A. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr. Opin. Cell Biol. 2009, 21:296-303.
25. Köhrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Mol. Cell Endocrinol. 1999, 151:103-119.
26. Krause K., Karger S., Schierhorn A., Poncin S., Many M.C., Fuhrer D. Proteomic profiling of cold thyroid nodules. Endocrinology 2007, 148:1754-1763.
27. Lengfelder E., Saussele S., Weisser A., Buchner T., Hehlmann R. Treatment concepts of acute promyelocytic leukemia. Crit. Rev. Oncol. Hematol. 2005, 56:261-274.
28. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res. 1996, 16:2415-2419.
29. Mazurek S., Boschek C.B., Hugo F., Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 2005, 15:300-308.
30. Musholt T.J., Hanack J., Brehm C., von Wasielewski R., Musholt P.B. Searching for non-RET molecular alterations in medullary thyroid carcinoma: expression analysis by mRNA differential display. World J. Surg. 2005, 29:472-482.
31. Mussunoor S., Murray G.I. The role of annexins in tumour development and progression. J. Pathol. 2008, 216:131-140.
32. Netea-Maier R.T., Hunsucker S.W., Hoevenaars B.M., Helmke S.M., Slootweg P.J., Hermus A.R., Haugen B.R., Duncan M.W. Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res. 2008, 68:1572-1580.
33. Niles R.M. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000, 16:1084-1089.
34. Obchoei S., Wongkhan S., Wongkham C., Li M., Yao Q., Chen C. Cyclophilin A: potential functions and therapeutic target for human cancer. Med. Sci. Monit. 2009, 15:221-232.
35. Schmutzler C., Hoang-Vu C., Rüger B., Kohrle J. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur. J. Endocrinol. 2004, 150:547-556.
36. Schmutzler C., Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur. J. Endocrinol. 2000, 143:15-24.
37. Schmutzler C., Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000, 10:393-406.
38. Sherman S.I. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J. Clin. Endocrinol. Metab. 2009, 94:1493-1499.
39. Simon D., Koehrle J., Reiners C., Boerner A.R., Schmutzler C., Mainz K., Goretzki P.E., Roeher H.D. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J. Surg. 1998, 22:569-574.
40. Simon D., Körber C., Krausch M., Segering J., Groth P., Görges R., Grünwald F., Müller-Gärtner H.W., Schmutzler C., Köhrle J., Röher H.D., Reiners C. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:775-782.
41. Trojanowicz B., Winkler A., Hammje K., Chen Z., Sekulla C., Glanz D., Schmutzler C., Mentrup B., Hombach-Klonisch S., Klonisch T., Finke R., Köhrle J., Dralle H., Hoang-Vu C. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. J. Mol. Endocrinol. 2009, 42:249-260.
42. Vander Heiden M.G., Christofk H.R., Schuman E., Subtelny A.O., Sharfi H., Harlow E.E., Xian J., Cantley L.C. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 2009, 10.1016/j.bcp.2009.12.003.
43. Vivaldi A., Miasaki F.Y., Ciampi R., Agate L., Collecchi P., Capodanno A., Pinchera A., Elisei R. Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. Mol. Cell Endocrinol. 2009, 307:142-148.
44. Zhang D., Tai L.K., Wong L.L., Chiu L.L., Sethi S.K., Koay ES Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell Proteom. 2005, 4:1686-1696.
45. Zhang B., Wang Y., Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett. 2009, 286:154-160.
46. Zhou R., Vander Heiden M.G., Rudin C.M. Genotoxic exposure is associated with alterations in glucose uptake and metabolism. Cancer Res. 2002, 62:3515-3520.